Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00259753
Status:
COMPLETED
Last Update Posted:
2008-08-05
First Post:
2005-11-30
Brief Title:
Safety and Efficacy Study of Small Interfering Ribonucleic Acid RNA Molecule Cand5 to Treat Wet Age-Related Macular Degeneration
Sponsor:
OPKO Health Inc
Organization:
OPKO Health Inc
Study Overview
Official Title:
A Phase II Randomized Double-Masked Controlled Dose Comparison Study of Cand5 for Intravitreal Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated With Wet Age-Related Macular Degeneration
Status:
COMPLETED
Status Verified Date:
2008-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The objective of this study is to evaluate the safety and preliminary efficacy of three doses of Cand5 Cand5 a small interfering RNA molecule that selectively silences the mRNA encoding for VEGF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None